- Home
- SOHO vs MYNZ Comparison
SOHO vs MYNZ Comparison
Compare SOHO & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOHO
- MYNZ
- Stock Information
- Founded
- SOHO 2004
- MYNZ 2021
- Country
- SOHO United States
- MYNZ Germany
- Employees
- SOHO N/A
- MYNZ N/A
- Industry
- SOHO Real Estate Investment Trusts
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- SOHO Real Estate
- MYNZ Health Care
- Exchange
- SOHO Nasdaq
- MYNZ Nasdaq
- Market Cap
- SOHO 16.1M
- MYNZ 16.0M
- IPO Year
- SOHO 2004
- MYNZ 2021
- Fundamental
- Price
- SOHO $0.83
- MYNZ $5.74
- Analyst Decision
- SOHO Hold
- MYNZ Buy
- Analyst Count
- SOHO 1
- MYNZ 3
- Target Price
- SOHO $1.50
- MYNZ $14.00
- AVG Volume (30 Days)
- SOHO 45.1K
- MYNZ 361.6K
- Earning Date
- SOHO 03-13-2025
- MYNZ 04-15-2025
- Dividend Yield
- SOHO N/A
- MYNZ N/A
- EPS Growth
- SOHO N/A
- MYNZ N/A
- EPS
- SOHO N/A
- MYNZ N/A
- Revenue
- SOHO $179,860,606.00
- MYNZ $917,203.00
- Revenue This Year
- SOHO N/A
- MYNZ $21.95
- Revenue Next Year
- SOHO $0.70
- MYNZ $30.77
- P/E Ratio
- SOHO N/A
- MYNZ N/A
- Revenue Growth
- SOHO 3.98
- MYNZ 16.23
- 52 Week Low
- SOHO $0.78
- MYNZ $0.18
- 52 Week High
- SOHO $1.54
- MYNZ $8.20
- Technical
- Relative Strength Index (RSI)
- SOHO 46.61
- MYNZ 48.77
- Support Level
- SOHO $0.78
- MYNZ $5.08
- Resistance Level
- SOHO $0.86
- MYNZ $8.16
- Average True Range (ATR)
- SOHO 0.04
- MYNZ 1.10
- MACD
- SOHO 0.01
- MYNZ -0.23
- Stochastic Oscillator
- SOHO 45.36
- MYNZ 21.15
About SOHO Sotherly Hotels Inc.
Sotherly Hotels Inc is engaged in Hotel operations. The company is a self-managed and self-administered lodging real estate investment trust that was formed to own, acquire, renovate, and reposition full-service, upscale, and upper-upscale hotel properties located in primary markets in the mid-Atlantic and southern United States. It generates revenue through the rooms, food, beverage, and other services. Geographically, the group has its presence in the regions of Florida, Georgia, Indiana, Maryland, North Carolina, Pennsylvania, Texas, and Virginia.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.